Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Inclusion Criteria:

* Has histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx, and larynx
* Has or be willing to provide tumor tissue for testing
* Has measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1
* Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Has adequate hematological function per protocol
* Has adequate renal function per protocol
* Has adequate hepatic function per protocol
* Agrees to use effective contraception while on the study and for 6-months after the end of the study
* Provides written informed consent(s)

Exclusion Criteria:

* Has left ventricular ejection fraction (LVEF) \<50%
* Had prior epidermal growth factor receptor (EGFR) targeted regimen
* Had prior anti-human epidermal growth factor receptor 3 (anti-HER3) therapy
* Had prior chemotherapy for recurrent/metastatic disease
* Had anti-cancer therapy between biopsy and submission of sample
* Has history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years
* Has known history of brain metastases or active brain metastases
* Has uncontrolled hypertension
* Has clinically significant electrocardiograph (ECG) findings
* Had myocardial infarction within 1 year before enrollment, symptomatic congestive heart failure, unstable angina, or arrhythmia requiring medication
* Had platinum-containing drug therapy with radiotherapy less than 6 months before study drug treatment
* Had therapeutic or palliative radiation therapy or major surgery within 4 weeks before study drug treatment